AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MyVax Personalized Immunotherapy shows promise in mantle cell lymphoma.
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- Genitope Corp. (GTOP) announced results of a phase II clinical trial evaluating MyVax Personalized Immunotherapy for the treatment of aggressive non-Hodgkin lymphoma, including mantle cell lymphoma (MCL).
The data were presented at the American Society of Hematology's 45th annual meeting and exposition by John P. Leonard, MD, assistant professor of medicine at Weill Cornell Medical College of Cornell University, and medical director of oncology services at New York-Presbyterian Hospital/Weill Cornell Medical Center.
The study examined two dosing strategies of MyVax Personalized Immunotherapy. The data suggest an accelerated schedule with more doses of MyVax Personalized Immunotherapy may be a safe and effective treatment following chemotherapy in individuals with aggressive lymphoma, including mantle cell lymphoma.
"Patients with mantle cell lymphoma typically respond well to chemotherapy, but the disease has the shortest median survival of all lymphoma subtypes and generally recurs quickly," said Leonard. "This study is an important step in the right direction, as we need to find an effective treatment for this difficult disease."
The study involved 27 patients with aggressive non-Hodgkin lymphoma, in complete or partial remission following CHOP chemotherapy. Each patient received one of two treatment schedules of MyVax Personalized Immunotherapy. Fourteen patients on Schedule A (5 with MCL) received five immunizations over 24 weeks, starting 3 months after completing chemotherapy.
The median time to ...
- MyVax Personalized Immunotherapy shows promise in mantle cell lymphoma.
- Newspaper article from: Immunotherapy Weekly January 7, 2004 700+ words
...trial evaluating MyVax Personalized Immunotherapy for the treatment...dosing strategies of MyVax Personalized Immunotherapy. The data suggest...with more doses of MyVax Personalized Immunotherapy may be a safe and...
- Update on pivotal phase III trial with MyVax Personalized Immunotherapy.
- Newspaper article from: Cancer Weekly March 16, 2004 700+ words
...product candidate, MyVax Personalized Immunotherapy, in patients with...of chemotherapy. MyVax Personalized Immunotherapy is manufactured using...those treated with MyVax Personalized Immunotherapy compared to the control...
- Genitope begins trials of MyVax personalized immunotherpy in CLL.(drug for...
- Newspaper article from: Pharma Marketletter March 6, 2006 700+ words
US biotechnology firm Genitope says it has begun a clinical trial of its personalized immunotherapy product MyVax in the treatment of patients with chronic lymphocytic leukemia. The compound is designed according to the genetic...
- Genitope Corporation Reports Initial Results of Phase 3 Clinical Trial of...
- Press release article from: Business Wire December 20, 2007 700+ words
...clearly show that MyVax personalized immunotherapy is a safe and active...Patients who received MyVax personalized immunotherapy and mounted a positive...path forward for MyVax personalized immunotherapy," said Dan W...
- Genitope Corporation's MyVax(R) Personalized Immunotherapy Pivotal Phase 3...
- Press release article from: Business Wire April 9, 2008 700+ words
...that Genitope is unlikely to be able to make MyVax personalized immunotherapy available to fNHL patients in the U.S...development, its lead product candidate was MyVax personalized immunotherapy, a patient-specific active immunotherapy...
- Genitope Corporation to Suspend Development of MyVax(R) Personalized...
- Press release article from: Business Wire March 11, 2008 700+ words
...clinical trial of MyVax[R] personalized immunotherapy in previously untreated follicular...suspend development of MyVax[R] personalized immunotherapy. Genitope is evaluating its...clinical trial of MyVax[R] personalized immunotherapy did not meet its primary endpoint...
- MyVax(TM) Personalized Immunotherapy Shows Promise in Mantle Cell Lymphoma; ASH...
- Press release article from: PR Newswire December 8, 2003 700+ words
...MyVax(TM) Personalized Immunotherapy for the treatment...MyVax(TM) Personalized Immunotherapy. The data suggest...MyVax(TM) Personalized Immunotherapy may be a safe...
- Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R)...
- Press release article from: PR Newswire May 21, 2007 700+ words
...evaluating the use of MyVax(R) personalized immunotherapy following primary treatment with...lymphoma (fNHL). MyVax(R) personalized immunotherapy is based on the unique genetic...timing for use of MyVax(R) personalized immunotherapy following treatment with the...